Real-world finerenone use in indian kidney and diabetes patients under review
NCT ID NCT06763146
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This study reviews medical records of 1200 Indian adults with chronic kidney disease and type 2 diabetes who started finerenone between August 2022 and April 2024. Researchers will analyze how doctors prescribed the drug, dose changes, and lab results like kidney function and potassium levels. The goal is to understand real-world usage patterns, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with a diagnosis of CKD associated with T2D who are initiated on finerenone under routine clinical management.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients from India (Indian ethnicity) diagnosed with CKD and T2D prior to initiating finerenone (per the standard diagnostic criteria) and initiated on finerenone per approved label. * Patient was prescribed finerenone for the first time (drug naïve) for the management of CKD and T2D between 1st August 2022 and 30th April 2024. * Age 18 years or older at the time of finerenone initiation. Exclusion Criteria: * eGFR \<25 mL/min/1.73 m\^2 * Serum potassium \>5.0 mmol/L * Type 1 diabetes is recorded in the patient record * Contraindications according to the local marketing authorization - Patient data will be excluded if below information is identified in the patient record at any point from index date to the end of observation period: * \- Pregnancy. * \- Lactation. * \- Patient taking concomitant medications that are strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin, telithromycin and nefazodone). * \- Addison's disease. * Patient was a part of an interventional clinical study between 1st August 2022 and 30th Nov 2024.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Many locations
Many Locations, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill takes aim at stubborn blood sugar
- Gene therapy shots aim to save legs from amputation in diabetes
- Can a breathing workout and walks help dialysis patients with irregular heartbeats?
- New pill takes aim at blood sugar in diabetes
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?
- Can a Patient's own kidney cells hold off dialysis?